MorphoSys Announces Re-election of Supervisory Board Members
Dr. Gerald Möller re-elected as Chairman of the Supervisory Board
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that at the Company's annual shareholder meeting on Wednesday,
May 14, 2008, its shareholders confirmed the reappointment of Dr.
Gerald Möller, Dr. Daniel Camus, Dr. Metin Colpan and Dr. Geoffrey N.
Vernon to the Supervisory Board. Dr. Möller was reappointed as
Chairman of the Supervisory Board.
In addition to the confirmation of the appointments to the
Supervisory Board, all other management proposals put to vote were
passed at the meeting, which took place in Munich.
As part of the shareholder assembly agenda, the shareholders approved
a three-for-one split of the Company's common stock.
"We are pleased to announce the re-election of all of our long-term
members of the Supervisory board and look forward to continue working
with them," commented Dr. Simon Moroney, Chief Executive Officer of
MorphoSys AG. "Their commitment and enormous contributions to
MorphoSys's successful development over the last several years have
been extremely valuable for the Company."
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/
HuCAL® and HuCAL GOLD® are registered trademarks of MorphoSys AG
For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj,
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.
